Wohlenberg Ole Jacob, Kortmann Carlotta, Meyer Katharina V, Scheper Thomas, Solle Dörte
Leibniz Universität Hannover Institut für Technische Chemie Hannover Germany.
Eng Life Sci. 2022 Dec 23;23(2):e202200056. doi: 10.1002/elsc.202200056. eCollection 2023 Feb.
Quality by Design (QbD) is one of the most important tools for the implementation of Process Analytical Technology (PAT) in biopharmaceutical production. For optimal characterization of a monoclonal antibody (mAb) upstream process a stepwise approach was implemented. The upstream was divided into three process stages, namely inoculum expansion, production, and primary recovery, which were investigated individually. This approach enables analysis of process parameters and associated intermediate quality attributes as well as systematic knowledge transfer to subsequent process steps. Following previous research, this study focuses on the primary recovery of the mAb and thereby marks the final step toward a holistic characterization of the upstream process. Based on gained knowledge during the production process evaluation, the cell viability and density were determined as critical parameters for the primary recovery. Directed cell viability adjustment was achieved using cytotoxic camptothecin in a novel protocol. Additionally, the cell separation method was added to the Design of Experiments (DoE) as a qualitative factor and varied between filtration and centrifugation. To assess the quality attributes after cell separation, the bioactivity of the mAb was analyzed using a cell-based assay and the purity of the supernatant was evaluated by measurement of process related impurities (host cell protein proportion, residual DNA). Multivariate data analysis of the compiled data confirmed the hypothesis that the upstream process has no significant influence on the bioactivity of the mAb. Therefore, process control must be tuned towards high mAb titers and purity after the primary recovery, enabling optimal downstream processing of the product. To minimize amounts of host cell proteins and residual DNA the cell viability should be maintained above 85% and the cell density should be controlled around 15 × 10 cells/ml during the cell removal. Thereby, this study shows the importance of QbD for the characterization of the primary recovery of mAbs and highlights the useful implementation of the stepwise approach over subsequent process stages.
质量源于设计(QbD)是生物制药生产中实施过程分析技术(PAT)的最重要工具之一。为了对单克隆抗体(mAb)上游工艺进行最佳表征,实施了一种逐步方法。上游工艺分为三个阶段,即种子扩增、生产和初步回收,并分别进行研究。这种方法能够分析工艺参数和相关的中间质量属性,并将系统知识转移到后续工艺步骤。继先前的研究之后,本研究聚焦于mAb的初步回收,从而标志着上游工艺全面表征的最后一步。基于生产过程评估中获得的知识,确定细胞活力和密度是初步回收的关键参数。在一个新方案中使用细胞毒性喜树碱实现了定向细胞活力调节。此外,细胞分离方法作为一个定性因素被添加到实验设计(DoE)中,并在过滤和离心之间变化。为了评估细胞分离后的质量属性,使用基于细胞的测定法分析mAb的生物活性,并通过测量工艺相关杂质(宿主细胞蛋白比例、残留DNA)评估上清液的纯度。对汇编数据的多变量数据分析证实了上游工艺对mAb生物活性没有显著影响这一假设。因此,必须在初步回收后将工艺控制调整为高mAb滴度和纯度,以实现产品的最佳下游加工。为了尽量减少宿主细胞蛋白和残留DNA的量,在细胞去除过程中细胞活力应保持在85%以上,细胞密度应控制在15×10⁶细胞/ml左右。因此,本研究表明了QbD对mAb初步回收表征的重要性,并突出了逐步方法在后续工艺阶段的有效实施。